JP2015078203A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015078203A5 JP2015078203A5 JP2014237428A JP2014237428A JP2015078203A5 JP 2015078203 A5 JP2015078203 A5 JP 2015078203A5 JP 2014237428 A JP2014237428 A JP 2014237428A JP 2014237428 A JP2014237428 A JP 2014237428A JP 2015078203 A5 JP2015078203 A5 JP 2015078203A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- organism
- composition
- erm
- mef
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 4
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 4
- 229960004099 azithromycin Drugs 0.000 claims 3
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000003835 ketolide antibiotic agent Substances 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 229930186147 Cephalosporin Natural products 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 229930182555 Penicillin Natural products 0.000 claims 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 2
- 102000002278 Ribosomal Proteins Human genes 0.000 claims 2
- 108010000605 Ribosomal Proteins Proteins 0.000 claims 2
- 241000194017 Streptococcus Species 0.000 claims 2
- 239000004098 Tetracycline Substances 0.000 claims 2
- 108010059993 Vancomycin Proteins 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229940124587 cephalosporin Drugs 0.000 claims 2
- 150000001780 cephalosporins Chemical class 0.000 claims 2
- 229960002227 clindamycin Drugs 0.000 claims 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229960003276 erythromycin Drugs 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 229940049954 penicillin Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 229960005404 sulfamethoxazole Drugs 0.000 claims 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims 2
- 229960002180 tetracycline Drugs 0.000 claims 2
- 229930101283 tetracycline Natural products 0.000 claims 2
- 235000019364 tetracycline Nutrition 0.000 claims 2
- 150000003522 tetracyclines Chemical class 0.000 claims 2
- 229960001082 trimethoprim Drugs 0.000 claims 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 2
- 229960003165 vancomycin Drugs 0.000 claims 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- 241000331201 Nocardia pneumoniae Species 0.000 claims 1
- 241000295644 Staphylococcaceae Species 0.000 claims 1
- 206010041925 Staphylococcal infections Diseases 0.000 claims 1
- 241000202898 Ureaplasma Species 0.000 claims 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000005001 aminoaryl group Chemical group 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- -1 ureido, carbamoyl Chemical group 0.000 claims 1
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10813708P | 2008-10-24 | 2008-10-24 | |
| US10811008P | 2008-10-24 | 2008-10-24 | |
| US10813408P | 2008-10-24 | 2008-10-24 | |
| US10816808P | 2008-10-24 | 2008-10-24 | |
| US10811208P | 2008-10-24 | 2008-10-24 | |
| US61/108,110 | 2008-10-24 | ||
| US61/108,168 | 2008-10-24 | ||
| US61/108,137 | 2008-10-24 | ||
| US61/108,134 | 2008-10-24 | ||
| US61/108,112 | 2008-10-24 | ||
| US16210909P | 2009-03-20 | 2009-03-20 | |
| US61/162,109 | 2009-03-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533398A Division JP5715569B2 (ja) | 2008-10-24 | 2009-10-24 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016080557A Division JP6309995B2 (ja) | 2008-10-24 | 2016-04-13 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015078203A JP2015078203A (ja) | 2015-04-23 |
| JP2015078203A5 true JP2015078203A5 (https=) | 2015-07-09 |
| JP5922210B2 JP5922210B2 (ja) | 2016-05-24 |
Family
ID=42119711
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533397A Expired - Fee Related JP5711135B2 (ja) | 2008-10-24 | 2009-10-24 | 胃腸疾患を治療するための方法 |
| JP2011533399A Expired - Fee Related JP5602748B2 (ja) | 2008-10-24 | 2009-10-24 | トリアゾール含有マクロライドを用いた生体防御 |
| JP2011533398A Active JP5715569B2 (ja) | 2008-10-24 | 2009-10-24 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2014167991A Expired - Fee Related JP6002185B2 (ja) | 2008-10-24 | 2014-08-20 | トリアゾール含有マクロライドを用いた生体防御 |
| JP2014237428A Active JP5922210B2 (ja) | 2008-10-24 | 2014-11-25 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2014237346A Active JP5908569B2 (ja) | 2008-10-24 | 2014-11-25 | 胃腸疾患を治療するための方法 |
| JP2016080557A Active JP6309995B2 (ja) | 2008-10-24 | 2016-04-13 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2018047869A Pending JP2018115177A (ja) | 2008-10-24 | 2018-03-15 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2019189322A Pending JP2020023544A (ja) | 2008-10-24 | 2019-10-16 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2021146793A Active JP7171860B2 (ja) | 2008-10-24 | 2021-09-09 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533397A Expired - Fee Related JP5711135B2 (ja) | 2008-10-24 | 2009-10-24 | 胃腸疾患を治療するための方法 |
| JP2011533399A Expired - Fee Related JP5602748B2 (ja) | 2008-10-24 | 2009-10-24 | トリアゾール含有マクロライドを用いた生体防御 |
| JP2011533398A Active JP5715569B2 (ja) | 2008-10-24 | 2009-10-24 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2014167991A Expired - Fee Related JP6002185B2 (ja) | 2008-10-24 | 2014-08-20 | トリアゾール含有マクロライドを用いた生体防御 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014237346A Active JP5908569B2 (ja) | 2008-10-24 | 2014-11-25 | 胃腸疾患を治療するための方法 |
| JP2016080557A Active JP6309995B2 (ja) | 2008-10-24 | 2016-04-13 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2018047869A Pending JP2018115177A (ja) | 2008-10-24 | 2018-03-15 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2019189322A Pending JP2020023544A (ja) | 2008-10-24 | 2019-10-16 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2021146793A Active JP7171860B2 (ja) | 2008-10-24 | 2021-09-09 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US9072759B2 (https=) |
| EP (4) | EP2362727B1 (https=) |
| JP (10) | JP5711135B2 (https=) |
| CN (4) | CN102245195B (https=) |
| AU (4) | AU2009308180B2 (https=) |
| DK (1) | DK2358379T3 (https=) |
| ES (3) | ES2565083T3 (https=) |
| HK (1) | HK1252140A1 (https=) |
| HR (1) | HRP20160222T1 (https=) |
| SI (1) | SI2358379T1 (https=) |
| WO (3) | WO2010048601A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638549A4 (en) | 2003-03-10 | 2011-06-15 | Optimer Pharmaceuticals Inc | NEW ANTIBACTERIAL AGENTS |
| EP2214484A4 (en) | 2007-10-25 | 2013-01-02 | Cempra Pharmaceuticals Inc | PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS |
| JP5711135B2 (ja) | 2008-10-24 | 2015-04-30 | センプラ ファーマシューティカルズ，インコーポレイテッド | 胃腸疾患を治療するための方法 |
| US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| ES2608285T3 (es) | 2009-09-10 | 2017-04-07 | Cempra Pharmaceuticals, Inc. | Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC |
| MX361413B (es) * | 2010-03-22 | 2018-12-05 | Cempra Pharmaceuticals Inc Star | Formas cristalinas de un macrólido y usos para las mismas. |
| CN102917708B (zh) | 2010-05-20 | 2015-11-25 | 森普拉制药公司 | 制备大环内酯和酮内酯及其中间体的方法 |
| EP2613630A4 (en) * | 2010-09-10 | 2014-01-15 | Cempra Pharmaceuticals Inc | HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES |
| NZ700182A (en) | 2012-03-27 | 2017-02-24 | Cempra Pharmaceuticals Inc | Parenteral formulations for administering macrolide antibiotics |
| AU2014239959A1 (en) | 2013-03-14 | 2015-10-01 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| CN105188712A (zh) | 2013-03-15 | 2015-12-23 | 森普拉制药公司 | 用于制备大环内酯抗菌剂的收敛方法 |
| JP6437523B2 (ja) | 2013-04-04 | 2018-12-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | マクロライドならびにそれらの調製および使用の方法 |
| CN104151382B (zh) * | 2014-08-08 | 2016-09-14 | 广东东阳光药业有限公司 | 一种固态大环内酯的晶型 |
| CN104311611B (zh) * | 2014-08-13 | 2017-01-18 | 广东东阳光药业有限公司 | 一种制备固态大环内酯的方法 |
| CN106998685A (zh) * | 2014-10-08 | 2017-08-01 | 哈佛大学的校长及成员们 | 14‑元酮内酯及其制备和使用方法 |
| EP3273969A4 (en) | 2015-03-25 | 2018-11-21 | President and Fellows of Harvard College | Macrolides with modified desosamine sugars and uses thereof |
| CN106554992A (zh) * | 2015-09-28 | 2017-04-05 | 中国疾病预防控制中心传染病预防控制所 | 检测耐红霉素弯曲菌的试剂盒 |
| WO2018152424A1 (en) * | 2017-02-17 | 2018-08-23 | Cempra Pharmaceuticals, Inc. | Triazole-containing macrolides and ophthalmic uses therefor |
| US10706191B2 (en) * | 2017-08-31 | 2020-07-07 | Google Llc | Systems and methods for generating a geo-level hierarchical Bayesian model |
| US11145299B2 (en) | 2018-04-19 | 2021-10-12 | X Development Llc | Managing voice interface devices |
Family Cites Families (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1354753A (en) | 1919-02-11 | 1920-10-05 | E M Lannes | Portable building |
| US2180006A (en) | 1936-09-09 | 1939-11-14 | Eastman Kodak Co | Process for the separation and refining of amines |
| GB891817A (en) | 1959-04-07 | 1962-03-21 | Upjohn Co | Improvements in or relating to injectable tetracyclic preparations |
| US3843787A (en) | 1969-01-15 | 1974-10-22 | Pierrel Spa | Water soluble derivative of erythromycin |
| US3668282A (en) | 1970-05-08 | 1972-06-06 | Stauffer Chemical Co | Stabilized mixture employing n-(beta-0,0-dialkyldithiophosphoryl) aryl sulfonamides |
| SE458505B (sv) | 1979-07-10 | 1989-04-10 | Lepetit Spa | Anvaendningen av rifamycin sv och salter daerav foer framstaellning av en beredning foer behandling av reumatoid artrit samt vissa av salterna och deras framstaellning |
| US4331803A (en) | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| JPS59175414A (ja) | 1983-03-23 | 1984-10-04 | Toyo Jozo Co Ltd | マクロライド抗生物質の安定な経口用製剤および安定化法 |
| US4742049A (en) | 1986-06-04 | 1988-05-03 | Abbott Laboratories | Semisynthetic erythromycin antibiotics |
| KR960000434B1 (ko) | 1986-12-17 | 1996-01-06 | 다이쇼 세이야꾸 가부시끼가이샤 | 에리스로마이신 a유도체 및 그의 제조 방법 |
| HU198913B (en) | 1987-09-03 | 1989-12-28 | Pliva Pharm & Chem Works | Process for producing 10-dihydro-10-deoxo-11-aza-erythronolide a-derivatives and pharmaceutical compositions containing them as active components |
| BE1001869A3 (fr) | 1988-10-12 | 1990-04-03 | Franz Legros | Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine. |
| IL99995A (en) * | 1990-11-21 | 1997-11-20 | Roussel Uclaf | Erythromycin derivatives, their preparation and pharmaceutical compositions containing them |
| US5985844A (en) | 1992-03-26 | 1999-11-16 | Merck & Co., Inc. | Homoerythromycin A derivatives modified at the 4"-and 8A-positions |
| FR2697524B1 (fr) | 1992-11-05 | 1994-12-23 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| US5527780A (en) * | 1992-11-05 | 1996-06-18 | Roussel Uclaf | Erythromycin derivatives |
| FR2718450B1 (fr) * | 1994-04-08 | 1997-01-10 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| FR2719587B1 (fr) | 1994-05-03 | 1996-07-12 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| WO1997001532A1 (en) * | 1995-06-28 | 1997-01-16 | Tokuyama Corporation | Ketonitrile derivatives and antibacterial agent and drug containing the same |
| FR2739620B1 (fr) * | 1995-10-09 | 1997-12-19 | Roussel Uclaf | Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs |
| US6274715B1 (en) | 1995-11-08 | 2001-08-14 | Abbott Laboratories | Tricyclic erythromycin derivatives |
| US5742049A (en) * | 1995-12-21 | 1998-04-21 | Bruker-Franzen Analytik Gmbh | Method of improving mass resolution in time-of-flight mass spectrometry |
| FR2742757B1 (fr) * | 1995-12-22 | 1998-01-30 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| FR2745290B1 (fr) | 1996-02-28 | 1998-04-03 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| US5719272A (en) | 1996-04-02 | 1998-02-17 | Abbott Laboratories | 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives |
| DE69733422T2 (de) * | 1996-09-04 | 2006-05-04 | Abbott Laboratories, Abbott Park | 6-0-substituierte ketoliden mit antibakteriellen wirkung |
| AU5597098A (en) | 1996-12-13 | 1998-07-03 | Eli Lilly And Company | Inhibitors of the enzymatic activity of psa |
| HN1998000074A (es) | 1997-06-11 | 1999-01-08 | Pfizer Prod Inc | Derivados de macrolidos c-4 sustituidos |
| US6407074B1 (en) | 1997-06-11 | 2002-06-18 | Pfizer Inc | C-4″-substituted macrolide derivatives |
| HN1998000086A (es) * | 1997-06-11 | 1999-03-08 | Pfizer Prod Inc | Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos. |
| EP0988308A1 (en) | 1997-06-11 | 2000-03-29 | Pfizer Products Inc. | 9-oxime erythromycin derivatives |
| HN1998000159A (es) | 1997-10-29 | 1999-02-09 | Monsanto Co | Derivados de 9- amino - 3 ceto eritromicina |
| IL135792A0 (en) | 1997-12-01 | 2001-05-20 | Abbott Lab | 6-o-alkyl derivatives of erythronolide b |
| ME00189B (me) * | 1998-03-26 | 2011-02-10 | Astellas Pharma Inc | Preparati sa neprekidnim oslobađanjem |
| FR2777282B1 (fr) * | 1998-04-08 | 2001-04-20 | Hoechst Marion Roussel Inc | Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments |
| US6387885B1 (en) | 1998-08-26 | 2002-05-14 | Abbott Laboratories | 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists |
| US6020521A (en) * | 1998-08-26 | 2000-02-01 | Abbott Laboratories | Macrolide LHRH antagonists |
| FR2785612A1 (fr) | 1998-11-10 | 2000-05-12 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| KR100317907B1 (ko) | 1998-11-24 | 2001-12-24 | 김 완 주 | 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법 |
| FR2786188B1 (fr) * | 1998-11-24 | 2002-10-31 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments |
| DE69933897T2 (de) | 1998-12-10 | 2007-03-15 | Pfizer Products Inc., Groton | Carbamat- und Carbazatketolid-Antibiotika |
| CA2359708C (en) | 1999-01-27 | 2005-10-25 | Pfizer Products Inc. | Ketolide antibiotics |
| CA2411293A1 (en) | 1999-01-28 | 2000-07-28 | Pfizer Products Inc. | Novel azalides and methods of making same |
| FR2789392B1 (fr) | 1999-02-04 | 2001-10-05 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| JP2000351794A (ja) | 1999-04-08 | 2000-12-19 | Hokuriku Seiyaku Co Ltd | エリスロマイシン誘導体 |
| AR023264A1 (es) | 1999-04-08 | 2002-09-04 | Hokuriku Pharmaceutical | Derivados de eritromicina |
| ATE340183T1 (de) | 1999-04-16 | 2006-10-15 | Kosan Biosciences Inc | Antiinfektiöse makrolidderivate |
| CA2370743A1 (en) | 1999-04-16 | 2000-10-26 | Dennis Hlasta | Ketolide antibacterials |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6420535B1 (en) * | 1999-06-07 | 2002-07-16 | Abbott Laboratories | 6-O-carbamate ketolide derivatives |
| US6437106B1 (en) * | 1999-06-24 | 2002-08-20 | Abbott Laboratories | Process for preparing 6-o-substituted erythromycin derivatives |
| WO2001010878A1 (fr) | 1999-08-06 | 2001-02-15 | Taisho Pharmaceutical Co., Ltd. | Derives d'erythromycine a |
| AU3337900A (en) | 1999-08-09 | 2001-03-05 | Eric Au | An apparatus for treating wastewater |
| US6096922A (en) | 1999-11-01 | 2000-08-01 | Air Products And Chemicals, Inc. | Process for the synthesis of dialkyl, diaryl, and arylalkyl aminosulfur trifluorides |
| KR100336447B1 (ko) | 1999-11-24 | 2002-05-15 | 민경윤 | 클라리스로마이신의 개선된 제조방법 |
| JP2001261694A (ja) * | 2000-03-06 | 2001-09-26 | Pfizer Prod Inc | ケトライド抗生物質 |
| RU2230748C2 (ru) | 2000-03-15 | 2004-06-20 | Ханми Фарм. Ко., Лтд. | Способ получения кларитромицина в виде кристаллов формы ii |
| NZ523693A (en) | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| US20020115621A1 (en) * | 2000-08-07 | 2002-08-22 | Wei-Gu Su | Macrolide antibiotics |
| GB0031312D0 (en) | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Macrolides |
| US20030143162A1 (en) | 2001-05-18 | 2003-07-31 | Speirs Robert John | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics |
| CA2451391A1 (en) | 2001-07-03 | 2003-01-16 | Chiron Corporation | C12 modified erythromycin macrolides and ketolides having antibacterial activity |
| US20030176327A1 (en) * | 2001-10-25 | 2003-09-18 | Cassell Gail Houston | Antibiotics for treating biohazardous bacterial agents |
| BR0307898A (pt) | 2002-02-22 | 2004-12-07 | Pharmacia Corp | Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio |
| JP4638225B2 (ja) | 2002-05-30 | 2011-02-23 | ザ スクリプス リサーチ インスティテュート | 銅を触媒とするアジドとアセチレンのライゲーション |
| EP1553954A4 (en) | 2002-06-17 | 2009-12-23 | Epigenesis Pharmaceuticals Llc | DIHYDRATE DEHYDROEPIANDROSTERONE AND METHOD FOR THE TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE LUNG DISEASE, COMPOSITIONS THEREOF |
| RS20050008A (sr) | 2002-07-08 | 2007-06-04 | Pliva-Istraživački Institut D.O.O., | Nova jedinjenja,kompozicije i metode za lečenje inflamatornih oboljenja i stanja |
| TW200420573A (en) | 2002-09-26 | 2004-10-16 | Rib X Pharmaceuticals Inc | Bifunctional heterocyclic compounds and methods of making and using same |
| ITMI20022292A1 (it) | 2002-10-29 | 2004-04-30 | Zambon Spa | 9a-azalidi ad attivita' antiinfiammatoria. |
| EP1638549A4 (en) * | 2003-03-10 | 2011-06-15 | Optimer Pharmaceuticals Inc | NEW ANTIBACTERIAL AGENTS |
| US7163924B2 (en) * | 2003-04-25 | 2007-01-16 | Chiron Corporation | Ketolide derivatives |
| CA2523134A1 (en) | 2003-04-25 | 2004-11-11 | Chiron Corporation | Pyridyl substituted ketolide antibiotics |
| ES2278319T3 (es) | 2003-05-13 | 2007-08-01 | Glaxo Group Limited | Nuevos compuestos con 14 y 15 miembros en el anillo. |
| US20050014706A1 (en) * | 2003-07-14 | 2005-01-20 | Kanakeshwari Falzari | Method of treating tuberculosis |
| US7457520B2 (en) * | 2003-07-24 | 2008-11-25 | Time Warner Cable, Inc. | Technique for providing a virtual digital video recorder service through a communications network |
| GB0402578D0 (en) | 2004-02-05 | 2004-03-10 | Cambridge Theranostics Ltd | Methods of treatment of atherosclerosis |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| WO2005105821A2 (en) | 2004-04-28 | 2005-11-10 | Alembic Limited | Process for the preparation of telithromycin |
| WO2005108412A1 (en) | 2004-05-06 | 2005-11-17 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Ester linked macrolides useful for the treatment of microbial infections |
| US20080287376A1 (en) * | 2004-07-28 | 2008-11-20 | Mohammad Salman | Ketolide Derivatives as Antibacterial Agents |
| GB0424958D0 (en) | 2004-11-11 | 2004-12-15 | Glaxo Group Ltd | Novel compounds |
| GB0424959D0 (en) | 2004-11-11 | 2004-12-15 | Glaxo Group Ltd | Novel compounds |
| JP2008526947A (ja) | 2005-01-14 | 2008-07-24 | グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ | 抗マラリア活性を有する９ａ−カルバモイル−γ−アミノプロピル−および９ａ−チオカルバモイル−γ−アミノプロピル−アザリド |
| EP1836212B1 (en) | 2005-01-14 | 2011-09-07 | Glaxo Group Limited | Macrolide compounds containing biotin and photo-affinity group for macrolide target identification |
| ATE429921T1 (de) | 2005-01-14 | 2009-05-15 | Glaxosmithkline Zagreb | 9a-carbamoyl- und thiocarbamoylazalide mit antimalariawirkung |
| WO2006102283A2 (en) | 2005-03-22 | 2006-09-28 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids for treating premenstrual disorders |
| JP2009500356A (ja) | 2005-07-07 | 2009-01-08 | エラン ファーマ インターナショナル リミテッド | ナノ粒子クラリスロマイシン製剤 |
| EP1910346B1 (en) | 2005-07-19 | 2019-02-27 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist |
| WO2007051468A2 (en) | 2005-10-31 | 2007-05-10 | Leo Pharma A/S | Preparation of an antibiotic crystalline fusidic acid |
| GB0522715D0 (en) | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
| US20070167382A1 (en) | 2005-11-15 | 2007-07-19 | Nina Finkelstein | Crystalline and amorphous forms of telithromycin |
| US20090075916A1 (en) | 2005-11-23 | 2009-03-19 | Upadhyay Dilip J | Use of Macrolide Derivatives for Treating Acne |
| US20090005325A1 (en) * | 2005-11-23 | 2009-01-01 | Biswajit Bas | Ketolide Derivatives as Antibacterial Agents |
| DOP2006000268A (es) | 2005-12-22 | 2007-07-31 | Pfizer Prod Inc | Agentes antibacterianos |
| CN101045063B (zh) | 2006-03-28 | 2011-01-26 | 广州朗圣药业有限公司 | 注射用克拉霉素水溶性制剂 |
| RU2455308C2 (ru) | 2006-05-01 | 2012-07-10 | Тайсо Фармасьютикал Ко., Лтд. | Макролидные производные |
| JP2009539866A (ja) | 2006-06-05 | 2009-11-19 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換エリスロマイシンアナログの調製および有用性 |
| DE102006036199B4 (de) * | 2006-08-03 | 2016-01-07 | Deere & Company | Förderzusammenbau und Presse |
| CN101129383B (zh) * | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | 含氨基糖苷类抗生素的抗生素复方 |
| EP2214484A4 (en) | 2007-10-25 | 2013-01-02 | Cempra Pharmaceuticals Inc | PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS |
| US20090209547A1 (en) * | 2008-02-15 | 2009-08-20 | In Jong Kim | C-8 halogenated macrolides |
| JP5711135B2 (ja) * | 2008-10-24 | 2015-04-30 | センプラ ファーマシューティカルズ，インコーポレイテッド | 胃腸疾患を治療するための方法 |
| US9814657B2 (en) | 2009-04-27 | 2017-11-14 | Premier Dental Products Company | Buffered microencapsulated compositions and methods |
| WO2011008193A1 (en) | 2009-07-13 | 2011-01-20 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| ES2608285T3 (es) | 2009-09-10 | 2017-04-07 | Cempra Pharmaceuticals, Inc. | Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC |
| US20110119604A1 (en) | 2009-11-19 | 2011-05-19 | Clevest Solutions Inc. | System and method for a configurable and extensible allocation and scheduling tool |
| ES2637072T3 (es) | 2010-03-10 | 2017-10-10 | Cempra Pharmaceuticals, Inc. | Formulación parenteral de antibióticos macrólidos |
| MX361413B (es) | 2010-03-22 | 2018-12-05 | Cempra Pharmaceuticals Inc Star | Formas cristalinas de un macrólido y usos para las mismas. |
| CN102917708B (zh) | 2010-05-20 | 2015-11-25 | 森普拉制药公司 | 制备大环内酯和酮内酯及其中间体的方法 |
| US8247394B2 (en) | 2010-06-02 | 2012-08-21 | Cempra Pharmaceuticals Inc. | Methods of treating urethritis and related infections using fusidic acid |
| US9260473B2 (en) | 2010-07-19 | 2016-02-16 | Virginia Commonwealth University | Bivalent multifunctional ligands targeting Aβ oligomers as treatment for Alzheimer's disease |
| US20130164351A1 (en) | 2010-08-30 | 2013-06-27 | Cempra Pharmaceuticals Inc. | Methods of treating bacterial infections through pulmonary delivery of fusidic acid |
| EP2613630A4 (en) | 2010-09-10 | 2014-01-15 | Cempra Pharmaceuticals Inc | HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES |
| WO2012042534A2 (en) | 2010-09-28 | 2012-04-05 | Glenmark Generics Limited | Processes for the preparation of r-sitagliptin and intermediates thereof |
| JP6072778B2 (ja) | 2011-05-23 | 2017-02-01 | シーイーエム—１０２ ファーマシューティカルズ，インコーポレイテッド | フシジン酸を含む組成物およびそのためのパッケージ |
| RU2578370C2 (ru) | 2011-08-27 | 2016-03-27 | Вокхардт Лимитед | Производные 1,6- диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней |
| MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| US8461188B2 (en) | 2011-10-20 | 2013-06-11 | Trius Therapeutics, Inc. | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use |
| NZ700182A (en) | 2012-03-27 | 2017-02-24 | Cempra Pharmaceuticals Inc | Parenteral formulations for administering macrolide antibiotics |
| AU2014239959A1 (en) | 2013-03-14 | 2015-10-01 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| CN105188712A (zh) | 2013-03-15 | 2015-12-23 | 森普拉制药公司 | 用于制备大环内酯抗菌剂的收敛方法 |
| JP6437523B2 (ja) | 2013-04-04 | 2018-12-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | マクロライドならびにそれらの調製および使用の方法 |
| CN106132969A (zh) | 2014-02-14 | 2016-11-16 | 森普拉制药公司 | 用于治疗糖尿病和肝病的组合物和方法 |
| WO2015181723A1 (en) | 2014-05-27 | 2015-12-03 | Dipharma Francis S.R.L. | Azidoalkylamine salts and their use as intermediates |
| SG11201700827RA (en) | 2014-08-05 | 2017-03-30 | Cempra Pharmaceuticals Inc | Powder oral suspension formulations of antibacterial agents |
| JP6773672B2 (ja) | 2015-03-06 | 2020-10-21 | センプラ ファーマシューティカルズ，インコーポレイテッド | フルオロケトライドを調製するための方法 |
-
2009
- 2009-10-24 JP JP2011533397A patent/JP5711135B2/ja not_active Expired - Fee Related
- 2009-10-24 CN CN200980150068.5A patent/CN102245195B/zh not_active Expired - Fee Related
- 2009-10-24 AU AU2009308180A patent/AU2009308180B2/en not_active Ceased
- 2009-10-24 WO PCT/US2009/061978 patent/WO2010048601A1/en not_active Ceased
- 2009-10-24 US US13/125,550 patent/US9072759B2/en not_active Expired - Fee Related
- 2009-10-24 CN CN200980146721.0A patent/CN102223794B/zh not_active Expired - Fee Related
- 2009-10-24 US US13/125,551 patent/US8791080B2/en not_active Expired - Fee Related
- 2009-10-24 ES ES09822828.1T patent/ES2565083T3/es active Active
- 2009-10-24 WO PCT/US2009/061976 patent/WO2010048599A1/en not_active Ceased
- 2009-10-24 JP JP2011533399A patent/JP5602748B2/ja not_active Expired - Fee Related
- 2009-10-24 JP JP2011533398A patent/JP5715569B2/ja active Active
- 2009-10-24 WO PCT/US2009/061977 patent/WO2010048600A1/en not_active Ceased
- 2009-10-24 DK DK09822828.1T patent/DK2358379T3/en active
- 2009-10-24 EP EP09822827.3A patent/EP2362727B1/en not_active Not-in-force
- 2009-10-24 EP EP09822828.1A patent/EP2358379B1/en not_active Not-in-force
- 2009-10-24 EP EP15186676.1A patent/EP3031460A1/en not_active Withdrawn
- 2009-10-24 ES ES09822827.3T patent/ES2677007T3/es active Active
- 2009-10-24 SI SI200931385A patent/SI2358379T1/sl unknown
- 2009-10-24 AU AU2009308181A patent/AU2009308181B2/en not_active Ceased
- 2009-10-24 CN CN201711145739.1A patent/CN107854477A/zh active Pending
- 2009-10-24 HR HRP20160222TT patent/HRP20160222T1/hr unknown
- 2009-10-24 AU AU2009308182A patent/AU2009308182B2/en not_active Ceased
- 2009-10-24 CN CN201610045028.6A patent/CN105616437A/zh active Pending
- 2009-10-24 US US13/125,555 patent/US8796232B2/en not_active Expired - Fee Related
- 2009-10-24 EP EP09822826.5A patent/EP2365747B1/en not_active Not-in-force
- 2009-10-24 ES ES09822826.5T patent/ES2676168T3/es active Active
-
2014
- 2014-06-19 US US14/309,178 patent/US9439918B2/en not_active Expired - Fee Related
- 2014-06-19 US US14/309,202 patent/US9901592B2/en not_active Expired - Fee Related
- 2014-08-20 JP JP2014167991A patent/JP6002185B2/ja not_active Expired - Fee Related
- 2014-11-25 JP JP2014237428A patent/JP5922210B2/ja active Active
- 2014-11-25 JP JP2014237346A patent/JP5908569B2/ja active Active
-
2015
- 2015-05-29 US US14/725,247 patent/US9669046B2/en not_active Expired - Fee Related
-
2016
- 2016-04-13 JP JP2016080557A patent/JP6309995B2/ja active Active
- 2016-04-28 AU AU2016202707A patent/AU2016202707A1/en not_active Abandoned
-
2018
- 2018-01-19 US US15/875,187 patent/US20180369262A1/en not_active Abandoned
- 2018-03-15 JP JP2018047869A patent/JP2018115177A/ja active Pending
- 2018-09-07 HK HK18111531.3A patent/HK1252140A1/zh unknown
-
2019
- 2019-10-16 JP JP2019189322A patent/JP2020023544A/ja active Pending
-
2021
- 2021-09-09 JP JP2021146793A patent/JP7171860B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015078203A5 (https=) | ||
| JP2012506871A5 (https=) | ||
| JP2012506870A5 (https=) | ||
| JP2020097577A5 (https=) | ||
| CL2018002009A1 (es) | Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras. | |
| EP3552611A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER WITH CRYSTALLINE TETRAARSEN HEXOXIDE POLYMORPH | |
| JP2015078220A5 (https=) | ||
| JP2018024670A5 (https=) | ||
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| EP4616908A3 (en) | Oxysterols and methods of use thereof | |
| JP2013519675A5 (https=) | ||
| JP2015061858A5 (https=) | ||
| HRP20151368T1 (hr) | C7-fluor supstituirani spojevi tetraciklina | |
| JP2015528502A5 (https=) | ||
| JP2014500861A5 (https=) | ||
| JP2017514910A5 (https=) | ||
| CL2021002263A1 (es) | Compuestos antibacterianos (solicitud divisional 202001147) | |
| JP2011530534A5 (https=) | ||
| WO2017117070A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| JP2016505007A5 (https=) | ||
| JP2017503850A5 (https=) | ||
| JP2013523761A5 (https=) | ||
| JP2015528468A5 (https=) | ||
| MX385203B (es) | Compuestos y métodos para tratar infecciones bacterianas. | |
| JP2017518982A5 (https=) |